<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443844</url>
  </required_header>
  <id_info>
    <org_study_id>16.02.2015 20/03</org_study_id>
    <nct_id>NCT02443844</nct_id>
  </id_info>
  <brief_title>Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diskapi Teaching and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diskapi Teaching and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare medical and surgical treatments of benign prostate
      hyperplasia in patients who have non muscle invasive bladder cancer for tumour recurrence and
      progression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>Bladder cancer recurrence rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression</measure>
    <time_frame>3 years</time_frame>
    <description>Bladder cancer progression rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>First group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transurethral Resection</intervention_name>
    <description>Endoscopic treatment of bladder cancer</description>
    <arm_group_label>Second Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Medical treatment for benign prostate hyperplasia</description>
    <arm_group_label>First group</arm_group_label>
    <other_name>alfa blocker treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have non muscle invasive bladder cancer male patients patients between
             40-80 years old

        Exclusion Criteria:

          -  Patients who have previous prostate surgery Patients who have muscle invasive bladder
             cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nihat Karakoyunlu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dıskapı TRH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nihat Karakoyunlu, MD</last_name>
    <phone>00905324747134</phone>
    <email>nkarakoyunlu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Turkish Ministry of Health Dıskapı Yıldırım Beyazıt Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nihat Karakoyunlu, MD</last_name>
      <phone>00905324747134</phone>
      <email>nkarakoyunlu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nihat Karakoyunlu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Li S, Zeng XT, Ruan XL, Wang XH, Guo Y, Yang ZH. Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: A systematic review and meta-analysis. Exp Ther Med. 2012 Oct;4(4):685-692. Epub 2012 Aug 9.</citation>
    <PMID>23170127</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diskapi Teaching and Research Hospital</investigator_affiliation>
    <investigator_full_name>Nihat Karakoyunlu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>treatment</keyword>
  <keyword>recurrence</keyword>
  <keyword>progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

